Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphael, Ritchie, Ellen K., Sekeres, Mikkael A., Barnard, John D., Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Fathi, Amir T., Roboz, Gail J., Fenaux, Pierre, Litzow, Mark R., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Germing, Ulrich, Bergua, Juan Miguel, Serrano, Josefina, Gore, Steven D., Zeidan, Amer M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916007/
https://ncbi.nlm.nih.gov/pubmed/29685952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados